Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GRFS 
Grifols SA ADR (GRFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: GRFS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.19
1 Year Target Price $12.19
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.12% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.13B USD | Price to earnings Ratio 34.78 | 1Y Target Price 12.19 |
Price to earnings Ratio 34.78 | 1Y Target Price 12.19 | ||
Volume (30-day avg) 2 | Beta 1 | 52 Weeks Range 6.19 - 9.96 | Updated Date 07/10/2025 |
52 Weeks Range 6.19 - 9.96 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.65% | Operating Margin (TTM) 16.42% |
Management Effectiveness
Return on Assets (TTM) 3.99% | Return on Equity (TTM) 3.45% |
Valuation
Trailing PE 34.78 | Forward PE 11.43 | Enterprise Value 18797153925 | Price to Sales(TTM) 1.1 |
Enterprise Value 18797153925 | Price to Sales(TTM) 1.1 | ||
Enterprise Value to Revenue 2.22 | Enterprise Value to EBITDA 10.79 | Shares Outstanding 258224000 | Shares Floating 560963286 |
Shares Outstanding 258224000 | Shares Floating 560963286 | ||
Percent Insiders - | Percent Institutions 58.6 |
Upturn AI SWOT
Grifols SA ADR
Company Overview
History and Background
Grifols was founded in 1909 in Barcelona, Spain. It is a global healthcare company specializing in plasma-derived therapies. Over the years, it has expanded internationally through acquisitions and organic growth, becoming a leading producer of plasma-derived protein therapies.
Core Business Areas
- Bioscience: Develops and manufactures plasma-derived protein therapies used to treat rare, chronic, and life-threatening conditions. This is Grifols' largest segment.
- Diagnostic: Develops, manufactures, and markets in-vitro diagnostic products, including transfusion medicine, hemostasis, and immunoassay solutions.
- Bio Supplies: Provides biological products for research and manufacturing, including plasma, antibodies, and other reagents.
- Hospital: Provides hospital pharmacy IV solutions and provides IV tools and pharmacy services.
Leadership and Structure
Grifols SA ADR is led by a Board of Directors and a management team. The company operates with a global structure, with regional divisions and functional departments.
Top Products and Market Share
Key Offerings
- Albumin: Albumin is a plasma protein used to treat various conditions, including hypovolemia and burns. Grifols is a significant player in the albumin market, competing with CSL Behring and Takeda. Market share varies regionally. Revenues are estimated around 1-2 billion USD annually.Competitors are CSL and Takeda.
- Intravenous Immunoglobulin (IVIG): IVIG is used to treat immune deficiencies and autoimmune disorders. Grifols holds a substantial share of the IVIG market globally, facing competition from CSL Behring, Takeda, and Octapharma. Revenues are estimated around 3-4 billion USD annually. Competitors are CSL, Takeda, and Octapharma.
- Alpha-1 Antitrypsin (AAT): AAT is used to treat Alpha-1 antitrypsin deficiency, a genetic disorder. Grifols markets Prolastin, a leading AAT product. Competitors are CSL and Takeda. Revenue around 500 -750 Million USD annually.
- Factor VIII: Factor VIII treats hemophilia A. Competitors are Novo Nordisk, Roche, and Takeda. Revenue estimates around 300 million USD Annually.
Market Dynamics
Industry Overview
The plasma-derived therapies industry is characterized by high barriers to entry, stringent regulations, and increasing demand driven by aging populations and expanding indications. Plasma supply is critical, and competition for donors is intense.
Positioning
Grifols is a leading player in the plasma-derived therapies market, with a vertically integrated business model, from plasma collection to manufacturing and distribution. Its competitive advantages include its extensive plasma collection network and strong R&D capabilities.
Total Addressable Market (TAM)
The global plasma-derived therapies market is expected to reach over $45 billion by 2030. Grifols is well-positioned to capture a significant share of this expanding market through its established product portfolio and strategic investments.
Upturn SWOT Analysis
Strengths
- Large plasma collection network
- Diversified product portfolio
- Global presence
- Strong R&D capabilities
- Vertically integrated business model
Weaknesses
- High debt levels
- Plasma supply chain vulnerabilities
- Regulatory scrutiny
- Operational inefficiencies
Opportunities
- Expanding indications for plasma-derived therapies
- Growth in emerging markets
- Technological advancements in plasma fractionation
- Strategic partnerships and acquisitions
Threats
- Competition from biosimilars
- Plasma supply disruptions
- Economic downturns
- Changes in reimbursement policies
- Increased regulatory burdens
Competitors and Market Share
Key Competitors
- CSL.AX
- TAK
- OCGN
Competitive Landscape
Grifols faces intense competition in the plasma-derived therapies market. Its key advantages include its large plasma collection network and diversified product portfolio. Its disadvantages include its high debt levels and regulatory scrutiny.
Major Acquisitions
Biotest US LLC
- Year: 2022
- Acquisition Price (USD millions): 1100
- Strategic Rationale: Expanded plasma collection network and increased production capacity.
Growth Trajectory and Initiatives
Historical Growth: Grifols has experienced strong growth over the past decade, driven by organic expansion and acquisitions. However, growth has slowed in recent years due to the pandemic.
Future Projections: Analysts project moderate growth for Grifols in the coming years, driven by increasing demand for plasma-derived therapies and the company's efforts to improve profitability. Focus on reducing debt will be important.
Recent Initiatives: Recent initiatives include expanding plasma collection capacity, developing new products, and implementing cost-saving measures.
Summary
Grifols is a significant player in the plasma-derived therapies market with a strong presence and diversified product line. The company's key strength lies in its extensive plasma collection network, a critical asset in this industry. However, its high debt levels pose a significant challenge. Successful debt management and improvements in operational efficiencies are crucial for sustaining growth and maintaining a competitive edge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Grifols SA ADR Financial Reports
- Industry Analyst Reports
- Market Research Data
- Company Press Releases
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and thorough research. Market conditions can change rapidly, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Grifols SA ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2006-05-17 | CEO & Director Mr. Jose Ignacio Abia Buenache | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 23800 | Website https://www.grifols.com |
Full time employees 23800 | Website https://www.grifols.com | ||
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.